MidWest Drug Development Conference
Downtown Capitol District, Omaha, Neb. | Sept. 30-Oct. 1, 2019
2019-09-30 08:00:00
Register
Downloads
  • Pamphlet
  • Promotional Flyer
  • Map & Other Info
  • Program
  • Home
  • Schedule
  • Venue
  • Technologies
    • By category
      • Autoimmue/Inflammatory
      • Cancer
      • Cardiovascular/Renal
      • Central Nervous System
      • Drug Delivery
      • Infectious Diseases
      • Metabolic
      • Ophthalmology
      • Startups
    • By institution
      • Cincinnati Children’s
      • Colorado
      • Iowa
      • Kansas
      • Kansas St.
      • Kentucky
      • Mayo Clinic
      • Missouri
      • Missouri-KC
      • Nebraska
      • Notre Dame
      • Ohio State
      • Oklahoma
      • Purdue
      • South Dakota
      • Toldeo
      • Wisconsin
    • Startups
  • Sponsors
  • News
  • Contact
  • Home
  • Schedule
  • Venue
  • Technologies
    • By category
      • Autoimmue/Inflammatory
      • Cancer
      • Cardiovascular/Renal
      • Central Nervous System
      • Drug Delivery
      • Infectious Diseases
      • Metabolic
      • Ophthalmology
      • Startups
    • By institution
      • Cincinnati Children’s
      • Colorado
      • Iowa
      • Kansas
      • Kansas St.
      • Kentucky
      • Mayo Clinic
      • Missouri
      • Missouri-KC
      • Nebraska
      • Notre Dame
      • Ohio State
      • Oklahoma
      • Purdue
      • South Dakota
      • Toldeo
      • Wisconsin
    • Startups
  • Sponsors
  • News
  • Contact

VSV cDNA libraries for cancer immuno/virotherapy

Mayo Clinic

Mayo Clinic researchers have developed a novel technology to define new repertoires of tumor antigen(s) which work alone or in combination to generate anti-tumor immune responses. Definition of arrays of antigens which co-operate in vivo to cure established tumors will inform future strategies for novel clinical vaccines through the use of vesicular stomatis virus (VSV) with cDNA libraries constructed with selected, relevant and defined epitopes which can be readily manufactured for clinical use. This technology can be applied for the treatment of a broad range of different cancer types as well as to antigen discovery in diseases where pathology is induced by immune reactivity against a single or multiple target antigens. Researchers have specifically demonstrated that VSV that encodes N-Ras, cytochrome c (ctyc) and Tyrosinase-related protein 1(TYRP1), can be used to treat melanoma.

Logo

MIDWEST DRUG DEVELOPMENT CONFERENCE
Bringing together industry and the best university drug development researchers in the Midwest
Downtown Capitol District, Omaha, NE
Sept. 30-Oct. 1, 2019

Latest News
  • MidWest Drug Development Conference hits the mark again November 18, 2019
  • Limited discount codes remain for industry, investors August 28, 2019
  • Last chance for discounted room rate, offer expires Friday August 27, 2019
  • Special room rate available for early birds July 15, 2019
Twitter Hightlights
  • Big shout out to our contracts specialist Jeff Andersen, who recently won a Golden Stopwatch Award from @Addgene. W… https://t.co/zUt6gttkdx
    about 5 hours ago
  • RT @charlielitton: Important editorial from @OWHopinion re: the critical importance of @InvestNebraska & the need for more #startup support…
    3 days ago